A proposed management algorithm for late-onset efavirenz neurotoxicity

• Published in: South African medical journal Vol. 108; no. 4; pp. 271 - 274
• Main Authors: Cross, H M, Chetty, S, Asukile, M T, Hussey, H S, Lee Pan, E B, Tucker, L M
• Format: Journal Article
• Language: English
• Published: South Africa Health & Medical Publishing Group 28.03.2018
• Subjects: Care and treatment; Complications and side effects; Development and progression; Dosage and administration; Efavirenz; Isoniazid; Neurotoxicity syndromes; Risk factors
• ISSN: 0256-9574
• DOI: 10.7196/SAMJ.2017.v108i4.12914

A high proportion of HIV-positive patients in South Africa receive concomitant efavirenz (EFV) and isoniazid (INH) therapy. EFV is metabolised in the liver via CYP2B6, and genetic polymorphism of CYP2B6 is known to result in slowed metabolism of the drug. INH is also metabolised in the liver, causing inhibition of a pathway that plays an important role in slow EFV metabolisers. Concomitant INH use therefore affects plasma levels of EFV. EFV is well known to cause neuropsychiatric side-effects on initiation, and a recent adult case series described late-onset neurotoxicity in the form of subacute ataxia and encephalopathy in patients treated with EFV for a median of 2 years, in association with toxic plasma levels of the drug. We have seen an increase in cases of EFV toxicity presenting to our neurology referral unit. All cases have been in the context of recent initiation of concomitant INH. We therefore conducted a retrospective case record audit to describe these seven cases with the additional advantage of tertiary-level assessment. We outline the clinical features and investigation results, as well as outcomes after EFV was stopped. Our main objectives are to highlight the probable role of concomitant INH use in the development of this syndrome, and to suggest that only limited work-up may be warranted in suspected cases.